Denosumab does the trick for bone loss in breast cancer

Author：

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1653, 2008-01, pp. : 14-14

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Denosumab HALTs bone loss during AI therapy for breast cancer

Inpharma, Vol. 1, Iss. 1620, 2008-01 ,pp. : 3-4

Adis International

Access to resources Recommend Favorite

Treatment with aromatase inhibitors for breast cancer is associated with bone loss in postmenopausal women

By Adis International Limited

Drugs & Therapy Perspectives, Vol. 25, Iss. 10, 2009-10 ,pp. : 23-26

Adis International

Access to resources Recommend Favorite

Risedronic acid prevents bone loss in postmenopausal women with breast cancer, with or without aromatase inhibitor (AI) therapy,

Inpharma, Vol. 1, Iss. 1637, 2008-01 ,pp. : 18-18

Adis International

Access to resources Recommend Favorite

Anastrozole use does not appear to change bone mineral density (BMD) or bone turnover markers in postmenopausal Japanese women with breast cancer

Reactions Weekly, Vol. 1, Iss. 1122, 2006-01 ,pp. : 5-5

Adis International

Access to resources Recommend Favorite

Pharmacotherapy of bone metastases in breast cancer patients – an update

By Jacobs Carmel Simos Demetrios Addison Christina Ibrahim Mohammed Clemons Mark

Expert Opinion on Pharmacotherapy, Vol. 15, Iss. 8, 2014-06 ,pp. : 1109-1118

Informa Healthcare

Access to resources Recommend Favorite